NCT05688579View on ClinicalTrials.gov

Effect of MRA on Cardiovascular Disease in Patients With Hypertension and Hyperaldosteronemia

PHASE4Enrolling by invitationINTERVENTIONAL
Enrollment

8,000

Participants

Timeline

Start Date

April 16, 2023

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions
HypertensionHyperaldosteronaemia
Interventions
DRUG

Mineralocorticoid Receptor Antagonists(MRAs)

Participants will be treated with mineralocorticoid receptor antagonists(MRAs) in addition to the original antihypertensive drugs for 48 months.

OTHER

Blank control

Participants will be treated with the original antihypertensive drugs for 48 months.

Trial Locations (1)

830001

Hypertension Center of People's Hospital of Xinjiang Uygur Autonomous Region, Ürümqi

All Listed Sponsors
lead

Nanfang Li

OTHER